Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for ELVN

Stock NameEnliven Therapeutics Inc.
TickerELVN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS29337E1029

Show aggregate ELVN holdings

News associated with ELVN

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.20
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) has earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the […] - 2025-08-08 02:42:46
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in Stock
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares in the company, valued […] - 2025-07-22 07:14:55
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $22.66, for a total transaction of $22,660.00. Following the transaction, the chief financial officer directly owned 23,000 shares of the company’s […] - 2025-07-15 06:21:06
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Buy” from Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a […] - 2025-07-11 05:23:02
Enliven Therapeutics (NASDAQ:ELVN) Trading 7.9% Higher Following Analyst Upgrade
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price was up 7.9% on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. Approximately 171,529 shares traded […] - 2025-07-04 02:24:46
Exchange Traded Concepts LLC Reduces Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Exchange Traded Concepts LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,055 shares of the company’s stock after selling 1,428 shares during the period. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $119,000 as of its most […] - 2025-06-24 04:38:52
Rhumbline Advisers Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Rhumbline Advisers raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 4.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 52,502 shares of the company’s stock after acquiring an additional 2,466 shares during the period. Rhumbline Advisers’ holdings in Enliven Therapeutics were worth $1,033,000 […] - 2025-06-20 04:22:47
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 138.53% from the stock’s […] - 2025-06-18 03:08:46
Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group
Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […] - 2025-06-18 03:08:45
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven […] - 2025-06-17 02:08:49
Two Sigma Investments LP Decreases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Two Sigma Investments LP lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 33.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its […] - 2025-06-11 04:30:51
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,036 shares of the company’s stock after purchasing an additional 718 shares during the […] - 2025-05-30 04:55:02
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Buy” by Brokerages
Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-27 05:26:58
Voya Investment Management LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Voya Investment Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,702 shares of the company’s stock after selling 945 shares during the quarter. Voya […] - 2025-05-13 05:22:51
Marshall Wace LLP Has $931,000 Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
Marshall Wace LLP cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 70.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,382 shares of the company’s stock after selling 96,624 shares during the quarter. Marshall Wace LLP’s holdings in Enliven Therapeutics were worth $931,000 at the end […] - 2025-05-01 04:50:53
ExodusPoint Capital Management LP Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN)
ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $200,000. Other hedge funds have also added to or reduced […] - 2025-04-15 04:39:25
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Fmr LLC
Fmr LLC grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned about 0.13% […] - 2025-04-14 05:48:47
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Holdings Lowered by Corebridge Financial Inc.
Corebridge Financial Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 1,321 shares during the quarter. […] - 2025-04-10 04:49:04
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling
Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price traded down 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares were traded during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock […] - 2025-04-03 02:44:44
Tuesday's ETF Movers: BLOK, IHE
In trading on Tuesday, the Amplify Transformational Data Sharing ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Core Scientific, up about 8.1% and shares of Applied Digital, up about 6.6% on the da - 2025-04-01 13:04:57
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says
Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective lifted by HC Wainwright from $37.00 to $39.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set […] - 2025-03-24 04:13:03

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ELVN holdings

DateNumber of ELVN Shares HeldBase Market Value of ELVN SharesLocal Market Value of ELVN SharesChange in ELVN Shares HeldChange in ELVN Base ValueCurrent Price per ELVN Share HeldPrevious Price per ELVN Share Held
2025-11-12 (Wednesday)60,853ELVN holding decreased by -200USD 1,235,316ELVN holding increased by 36235USD 1,235,316-200USD 36,235 USD 20.3 USD 19.64
2025-11-11 (Tuesday)61,053USD 1,199,081ELVN holding increased by 56779USD 1,199,0810USD 56,779 USD 19.64 USD 18.71
2025-11-10 (Monday)61,053USD 1,142,302ELVN holding increased by 65938USD 1,142,3020USD 65,938 USD 18.71 USD 17.63
2025-11-07 (Friday)61,053USD 1,076,364ELVN holding decreased by -40906USD 1,076,3640USD -40,906 USD 17.63 USD 18.3
2025-11-06 (Thursday)61,053ELVN holding decreased by -200USD 1,117,270ELVN holding decreased by -15911USD 1,117,270-200USD -15,911 USD 18.3 USD 18.5
2025-11-05 (Wednesday)61,253ELVN holding decreased by -2000USD 1,133,181ELVN holding decreased by -69259USD 1,133,181-2,000USD -69,259 USD 18.5 USD 19.01
2025-11-04 (Tuesday)63,253ELVN holding decreased by -400USD 1,202,440ELVN holding decreased by -70620USD 1,202,440-400USD -70,620 USD 19.01 USD 20
2025-11-03 (Monday)63,653ELVN holding decreased by -400USD 1,273,060ELVN holding decreased by -227061USD 1,273,060-400USD -227,061 USD 20 USD 23.42
2025-10-31 (Friday)64,053USD 1,500,121ELVN holding decreased by -35229USD 1,500,1210USD -35,229 USD 23.42 USD 23.97
2025-10-30 (Thursday)64,053USD 1,535,350ELVN holding increased by 84550USD 1,535,3500USD 84,550 USD 23.97 USD 22.65
2025-10-29 (Wednesday)64,053USD 1,450,800ELVN holding increased by 70458USD 1,450,8000USD 70,458 USD 22.65 USD 21.55
2025-10-28 (Tuesday)64,053ELVN holding increased by 600USD 1,380,342ELVN holding increased by 22448USD 1,380,342600USD 22,448 USD 21.55 USD 21.4
2025-10-27 (Monday)63,453USD 1,357,894ELVN holding increased by 50128USD 1,357,8940USD 50,128 USD 21.4 USD 20.61
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ELVN by Blackrock for IE00B3VWM098

Show aggregate share trades of ELVN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12SELL-20020.62019.630 19.729USD -3,946 21.23 Profit of 300 on sale
2025-11-06SELL-20018.56017.810 17.885USD -3,577 21.28 Profit of 680 on sale
2025-11-05SELL-2,00019.00017.770 17.893USD -35,786 21.30 Profit of 6,809 on sale
2025-11-04SELL-40020.23018.630 18.790USD -7,516 21.31 Profit of 1,008 on sale
2025-11-03SELL-40023.31018.330 18.828USD -7,531 21.32 Profit of 995 on sale
2025-10-28BUY60021.55021.680 21.667USD 13,000 21.28
2025-10-24SELL-20020.61020.820 20.799USD -4,160 21.29 Profit of 97 on sale
2025-10-15BUY1,20021.73021.750 21.748USD 26,098 21.28
2025-10-03BUY5,54319.61020.193 20.135USD 111,607 21.29
2025-10-02BUY18219.92020.090 20.073USD 3,653 21.30
2025-09-30BUY36420.47020.900 20.857USD 7,592 21.31
2025-08-21SELL-16319.84020.275 20.231USD -3,298 21.37 Profit of 185 on sale
2025-07-31BUY48918.81019.440 19.377USD 9,475 21.39
2025-06-30SELL-32620.06021.210 21.095USD -6,877 21.42 Profit of 107 on sale
2025-06-25SELL-16321.50021.660 21.644USD -3,528 21.43 Loss of -35 on sale
2025-06-20SELL-32621.30022.070 21.993USD -7,170 21.44 Loss of -180 on sale
2025-05-30BUY5,67217.77018.250 18.202USD 103,242 21.50
2025-05-23BUY14416.40016.950 16.895USD 2,433 21.70
2025-05-19SELL-14416.85017.280 17.237USD -2,482 21.87 Profit of 667 on sale
2025-05-15SELL-43217.82020.000 19.782USD -8,546 21.95 Profit of 935 on sale
2025-05-12SELL-14419.01019.850 19.766USD -2,846 22.01 Profit of 323 on sale
2025-05-09SELL-14418.42019.670 19.545USD -2,814 22.04 Profit of 360 on sale
2025-04-30SELL-14418.94019.219 19.191USD -2,764 22.22 Profit of 436 on sale
2025-04-24SELL-28818.30018.570 18.543USD -5,340 22.37 Profit of 1,101 on sale
2025-04-17SELL-14416.53016.854 16.822USD -2,422 22.65 Profit of 839 on sale
2025-04-15SELL-43217.05018.140 18.031USD -7,789 22.78 Profit of 2,053 on sale
2025-04-14SELL-43217.19017.380 17.361USD -7,500 22.85 Profit of 2,369 on sale
2025-04-09SELL-57616.52017.190 17.123USD -9,863 23.08 Profit of 3,431 on sale
2025-04-07SELL-1,00817.87019.690 19.508USD -19,664 23.22 Profit of 3,746 on sale
2025-04-04SELL-1,45018.69020.040 19.905USD -28,862 23.28 Profit of 4,890 on sale
2025-03-31BUY14519.68021.160 21.012USD 3,047 23.42
2025-03-19SELL-29020.89021.180 21.151USD -6,134 23.65 Profit of 726 on sale
2025-03-14SELL-87020.74022.210 22.063USD -19,195 23.78 Profit of 1,492 on sale
2025-03-13SELL-29020.29021.120 21.037USD -6,101 23.83 Profit of 809 on sale
2025-03-12SELL-4,93021.02021.155 21.142USD -104,228 23.87 Profit of 13,447 on sale
2025-03-07SELL-29021.00022.290 22.161USD -6,427 24.02 Profit of 538 on sale
2025-03-06SELL-43521.46022.360 22.270USD -9,687 24.05 Profit of 776 on sale
2025-03-03SELL-14519.62021.238 21.076USD -3,056 24.24 Profit of 458 on sale
2025-02-28SELL-87020.83021.035 21.014USD -18,283 24.29 Profit of 2,853 on sale
2025-02-26SELL-14520.28020.750 20.703USD -3,002 24.43 Profit of 541 on sale
2025-02-25SELL-43520.13021.530 21.390USD -9,305 24.51 Profit of 1,356 on sale
2025-02-18BUY72521.82022.355 22.301USD 16,169 24.77
2025-02-13BUY14521.50022.910 22.769USD 3,302 24.96
2025-02-12BUY14522.05022.080 22.077USD 3,201 25.02
2025-02-11BUY43521.41021.820 21.779USD 9,474 25.10
2025-02-06BUY1,30522.47023.180 23.109USD 30,157 25.30
2025-01-27BUY14521.29022.280 22.181USD 3,216 26.10
2024-12-30BUY72522.39022.775 22.736USD 16,484 26.53
2024-12-06BUY58025.42025.960 25.906USD 15,025 26.73
2024-12-05BUY14523.25024.145 24.056USD 3,488 26.85
2024-12-04BUY72523.71023.980 23.953USD 17,366 26.96
2024-11-29BUY72524.38025.630 25.505USD 18,491 27.30
2024-11-27BUY58025.41025.670 25.644USD 14,874 27.46
2024-11-26BUY14524.35025.070 24.998USD 3,625 27.61
2024-11-25BUY4,49324.88025.640 25.564USD 114,859 27.74
2024-11-21BUY65025.41025.760 25.725USD 16,721 28.03
2024-11-20BUY39025.43026.480 26.375USD 10,286 28.17
2024-11-18BUY1,56024.90024.925 24.922USD 38,879 28.50
2024-11-12BUY1,04027.17028.220 28.115USD 29,240 28.59
2024-11-08BUY65028.96029.400 29.356USD 19,081 28.56
2024-11-07BUY1,95029.00029.785 29.706USD 57,928 28.53
2024-11-06BUY26029.55029.650 29.640USD 7,706 28.44
2024-10-31BUY13027.85029.090 28.966USD 3,766 28.77
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ELVN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19255,5122,440367,30069.6%
2025-09-18205,7420372,47655.2%
2025-09-17162,9261,997258,66063.0%
2025-09-16210,6140354,40959.4%
2025-09-15158,96815285,25855.7%
2025-09-12150,9770331,82845.5%
2025-09-1196,0600385,68624.9%
2025-09-1047,9496151,23231.7%
2025-09-09131,8830239,21455.1%
2025-09-08196,3068,811347,78556.4%
2025-09-0563,2560131,30948.2%
2025-09-0478,4350146,46853.6%
2025-09-03105,0050189,63455.4%
2025-09-0292,210308154,10759.8%
2025-08-29152,705246324,86747.0%
2025-08-28113,3720320,88435.3%
2025-08-27114,8532,880257,35044.6%
2025-08-2636,9370145,78925.3%
2025-08-25150,6680277,23854.3%
2025-08-22164,5360493,35133.4%
2025-08-21208,2231,982440,28247.3%
2025-08-2069,5641,006132,98752.3%
2025-08-1942,0583,41078,03253.9%
2025-08-1852,7763,411113,03046.7%
2025-08-1549,843607137,04436.4%
2025-08-1460,7670121,82349.9%
2025-08-1377,8340145,51653.5%
2025-08-1276,4110165,02446.3%
2025-08-1149,374080,19161.6%
2025-08-08148,399100336,54044.1%
2025-08-0775,0442,200122,75161.1%
2025-08-06123,11720222,05555.4%
2025-08-05103,5010245,37542.2%
2025-08-0436,934099,77437.0%
2025-08-01100,8650290,37934.7%
2025-07-3172,6650189,29338.4%
2025-07-3083,0290128,49264.6%
2025-07-2941,5270133,28631.2%
2025-07-2844,8201,104199,29022.5%
2025-07-2538,438675,23751.1%
2025-07-2472,74728125,30058.1%
2025-07-2327,864077,64335.9%
2025-07-2250,0680117,13742.7%
2025-07-2163,6827,051239,26926.6%
2025-07-1839,727258109,46436.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.